Gritstone Bio Return on Investment 2017-2024 | GRTSQ
Current and historical return on investment (ROI) values for Gritstone Bio (GRTSQ) over the last 10 years.
| Gritstone Bio ROI - Return on Investment Historical Data |
| Date |
TTM Net Income |
LT Investments & Debt |
Return on Investment |
| 2024-06-30 |
$-0.14B |
$0.06B |
-175.08% |
| 2024-03-31 |
$-0.15B |
$0.05B |
-149.10% |
| 2023-12-31 |
$-0.14B |
$0.09B |
-110.89% |
| 2023-09-30 |
$-0.14B |
$0.10B |
-94.20% |
| 2023-06-30 |
$-0.13B |
$0.14B |
-81.22% |
| 2023-03-31 |
$-0.13B |
$0.17B |
-98.45% |
| 2022-12-31 |
$-0.12B |
$0.19B |
-139.88% |
| 2022-09-30 |
$-0.12B |
$0.16B |
-305.13% |
| 2022-06-30 |
$-0.12B |
|
inf% |
| 2022-03-31 |
$-0.11B |
|
inf% |
| 2021-12-31 |
$-0.08B |
|
inf% |
| 2021-09-30 |
$-0.07B |
|
inf% |
| 2021-06-30 |
$-0.07B |
|
-301.08% |
| 2021-03-31 |
$-0.07B |
|
-305.38% |
| 2020-12-31 |
$-0.11B |
|
-455.91% |
| 2020-09-30 |
$-0.11B |
$0.09B |
-460.22% |
| 2020-06-30 |
$-0.11B |
|
inf% |
| 2020-03-31 |
$-0.11B |
|
inf% |
| 2019-12-31 |
$-0.10B |
|
inf% |
| 2019-09-30 |
$-0.09B |
|
-217.50% |
| 2019-06-30 |
$-0.08B |
|
-128.40% |
| 2019-03-31 |
$-0.07B |
|
-118.52% |
| 2018-12-31 |
$-0.07B |
$0.16B |
-108.64% |
| 2018-06-30 |
$-0.04B |
|
inf% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.016B |
|
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient?s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients? TSNA to drive the patient?s immune system to attack and destroy tumors.
|
